María-Victoria Mateos (University of Salamanca, Salamanca, Spain), leading expert in mulitple myeloma, shared her thoughts on the current challenges in CAR-T cell therapy and the strategies being investigated to address them. CAR-T therapy has introduced a new treatment modality to the triple-class refractory patient population, who had minimal effective treatment options previously.
Disclosures: María-Victoria Mateos discloses the following – Advisory Board or panel fees from Abbvie, Adaptive, Amgen, Celgene, GlaxoSmithKline, Genentech, Janssen, Oncopeptides, Pfizer, Regeneron, Roche, Sanofi and Takeda. Speaker’s Bureau fees from Amgen, Celgene, GlaxoSmithKline, Janssen and Takeda.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Nicola Cartridge.
View more multiple myeloma content:
- Dr María-Victoria Mateos (University of Salamanca, Salamanca, Spain) shares the recent updates in bispecific monoclonal antibodies for patients with refractory/relapsed multiple myeloma . Watch here on touchHAEMATOLOGY
- Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Watch here on touchONCOLOGY
- Dr Joseph Franz and Dr Sagar Lonial discuss the recent ATLAS study (ClinicalTrials.gov Identifier: NCT02659293) and optimal post-ASCT management in patients with multiple myeloma. Read here on touchONCOLOGY
